跳至主要内容
临床试验/NCT07676565
NCT07676565招募中不适用

Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study

Indiana University7 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2026年3月24日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
300
试验地点
7
主要终点
Change in HbA1c by type of therapy

研究概览

简要总结

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults ≥18 years of age
  • Clinical diagnosis of T1D
  • GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
  • Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
  • Willing and able to provide informed consent

排除标准

  • No exclusion criteria other than those not meeting inclusion criteria above

结局指标

主要结局

Change in HbA1c by type of therapy

时间窗: 1 year

Change in HbA1c from baseline to over 1 year by those receiving GLP-1RA and SGLTi

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Viral N. Shah

Professor of Medicine

Indiana University

研究点 (7)

Loading locations...

相似试验